Fall 2025 Kernel Newsletter

In this newsletter:

  • Kernel Product Launches
  • Bringing the Neuro to NeuroAI
  • New Website
  • Upcoming Events
  • Recent News and Publications

Most people reading this newsletter have never had their brain measured.

Changes in the brain often go unnoticed until the window for prevention has already passed.

Bryan founded Kernel nearly 10 years ago with $50M of his own capital because he knew the time was right to bring advanced neuro measurement into the real world. In this ambition, Kernel made the early decision to develop non-invasive neurotechnology to provide meaningful measures that everyone could benefit from.

As we developed our technology, we held ourselves to high standards — no gimmicks, no toys, no sci-fi fantasies. Only real science, deep technology development, and robust products.

Today, we are officially launching our first wellness products (Kernel Trackers), intended for use in longevity and wellness clinics. We started piloting our Brain Age Tracker at the beginning of the summer and currently have five clinics offering scans to their clients. You can see our growing list of clinics and their locations here.

Additionally, we are announcing our Cognition Tracker, a 30-minute deep dive into cognitive function. This test is unlike any other cognitive test available on the market as it combines individual performance data with Kernel Flow data (TD-fNIRS + EEG) to give a comprehensive age-normalized score.

Kernel Platform

We are excited to launch these products to bring detailed brain measurement to everyone for the first time.

Along with this product launch, we have published a fresh website to help guide consumers, clinics, developers, and researchers to the information and products they need. We’re seeing exciting new things from groups building on our platform in the fast-emerging field of NeuroAI. If you’ve been dreaming about building models on brain data, we’ve got the best solution for high-quality data collection at scale and are actively developing more advanced capabilities.

Kernel Markers

Finally, Kernel is continuing development work on our lineup of clinical products (Kernel Markers). We published results from our mild cognitive impairment (MCI) trial in July and expect readouts of our entire depression treatment prediction study by the end of the year. We will continue working to bring solutions to the market that improve patient outcomes and address the biggest challenges in neuro medicine. You can check out KerneLabs for opportunities to participate in new research and help build the next generation of Kernel Trackers and Markers.

Enough from me, see for yourself at www.kernel.com

Ryan

Upcoming Events

Kernel will be here, will you?

ISCTM Autumn Conference (October 9-11, Amsterdam) Presenting our latest work on depression severity monitoring in clinical trials.

HLTH (October 19-22, Las Vegas) Demoing Brain Age live in booth 1760-25 in the Digital Health Hub Foundation & StartUp Health Pavillion.

CNS Summit (November 2-5, Boston) Sharing updates on our novel approaches to monitoring trial site performance.

Neurotech Leaders Forum (November 6, San Francisco) Discussing how non-invasive neuro measurement can bring value to consumers in wellness applications.

Frontiers in Neuroengineering and Psychiatry workshop @ IEEE EMBS (November 11, San Diego) Moderating a panel discussion on commercializing neurotech for psychiatry — an investor perspective.

NeurIPS - Foundation Models for the Brain and Body (December 6, San Diego) Demoing advances to our AI platform for real-time inference.

© 2025 Kernel

If you do not wish to receive further communication like this, unsubscribe here.